Compare · NVO vs PRGO
NVO vs PRGO
Side-by-side comparison of Novo Nordisk A/S (NVO) and Perrigo Company plc (PRGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PRGO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 128.0x PRGO ($1.50B).
- Over the past year, NVO is down 43.1% and PRGO is down 58.6% - NVO leads by 15.5 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 2 for PRGO).
- NVO has more recent analyst coverage (25 ratings vs 11 for PRGO).
- Company
- Novo Nordisk A/S
- Perrigo Company plc
- Price
- $42.94-1.84%
- $10.84+1.45%
- Market cap
- $191.82B
- $1.50B
- 1M return
- -6.14%
- -11.55%
- 1Y return
- -43.10%
- -58.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 7
- 2
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest PRGO
- SEC Form 144 filed by Perrigo Company plc
- Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
- Director Parker Geoffrey M. exercised 7,305 units of Ordinary Shares at a strike of $10.84 and covered exercise/tax liability with 3,507 units of Ordinary Shares, increasing direct ownership by 13% to 32,710 units (SEC Form 4)
- SEC Form 4 filed by CEO Lockwood-Taylor Patrick
- SEC Form 4 filed by EVP & Chief Financial Officer Bezerra Eduardo Guarita
- SEC Form 4 filed by EVP and CSO Lennox Abigail
- SEC Form 4 filed by EVP and President of CSCI Khoury Roberto
- SEC Form 4 filed by EVP & CBDO Ball David
- SEC Form 4 filed by EVP & CHRO Willis Robert
- SEC Form 4 filed by EVP, Supply, Ops, Strategy Winterman Matthew John